Ischaemic Cardiac Outcomes in Patients With Atrial Fibrillation Treated With Vitamin K Antagonism or Factor Xa Inhibition: Results From the ROCKET AF Trial

Study Questions:

What is the incidence of cardiovascular (CV) events in a large population of patients with atrial fibrillation (AF) receiving anticoagulant therapy, and the risk of CV events with rivaroxaban compared with warfarin?